Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 2031-2036

  Estepp, Jeremie H ^a   Winter, Bryan ^a   Johnson, Margery ^a   Smeltzer, Matthew P ^a   Howard, Scott C ^a   Hankins, Jane S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Medication adherence; Sickle cell anemia; Text messages

Indexed keywords

BILIRUBIN; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CHILD HOSPITALIZATION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; MOBILE PHONE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; REMINDER SYSTEM; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; TEXT MESSAGING; ANEMIA, SICKLE CELL; MAXIMUM TOLERATED DOSE; PRESCHOOL CHILD;

ADOLESCENT; ANEMIA, SICKLE CELL; CELL PHONES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; MALE; MAXIMUM TOLERATED DOSE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES;

EID: 84922603278     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25177     Document Type: Article

References (27)

1. Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med 2013; 3:a011783.
2. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010; 24:199-214.
3. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005; 106:2269-2275.
4. Nottage KA, Hankins JS, Smeltzer M, et al. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS One 2013; 8:e72077.
5. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). The Lancet 2011; 377:1663-1672.
6. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039-2045.
7. Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86:273-277.
8. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics 2013; 132:677-683.
9. Estepp JH, Smeltzer MP, Wang WC, et al. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol 2013; 161:402-405.
10. Aygun B, Mortier NA, Smeltzer MP, et al. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol 2013; 88:116-119.
11. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94:1550-1554.
12. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300-5311.
13. Brawley OW, Cornelius LJ, Edwards LR, et al. National institutes of health consensus development conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932-938.
14. Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer 2013; 60:653-658.
15. Thornburg C, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 2010; 156:415-419.
16. Lenhart A, Ling R, Campbell S, et al. Teens and mobile phones: Text messaging explodes as teens embrace it as the centerpiece of their communication strategies with friends. Pew Research Center; Washington, D.C: (April 20, 2010). http://www.pewinternet.org/2010/04/20/teens-and-mobile-phones/
17. Tercyak KP, Abraham AA, Graham AL, et al. Association of multiple behavioral risk factors with adolescents' willingness to engage in eHealth promotion. J Pediatr Psychol 2009; 34:457-469.
18. Shah N, Jonassaint J, De Castro L. Patients welcome the Sickle Cell Disease Mobile Application to Record Symptoms via Technology (SMART). Hemoglobin 2014; 38:99-103.
19. Stockwell MS, Kharbanda EO, Martinez RA, et al. Effect of text messaging intervention on influenza vaccination in an urban, low-income pediatric and adolescent population. JAMA 2012; 1702-1708.
20. Franklin VL, Waller A, Pagliari C, et al. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med 2006; 23:1332-1338.
21. Armstrong AW, Watson AJ, Makredes M, et al. Text-message reminders to improve sunscreen use: A randomized, controlled trial using electronic monitoring. Arch Dermatol 2009; 145:1230-1236.
22. Miloh T, Annunziato R, Arnon R, et al. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. Pediatrics 2009; 124:e844-e850.
23. Rami B, Popow C, Horn W, et al. Telemedical support to improve glycemic control in adolescents with type 1 diabetes mellitus. Eur J Pediatr 2006; 165:701-705.
24. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15:565-574.
25. Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol 2011; 86:804-806.
26. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317-1322.
27. Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal Pediatr 2001; 139:790-796.